- Policy
- Discard Moon Care Policy
- by Lee, Jeong-Hwan Dec 19, 2022 04:34am
- President Yoon Suk Yeol announced a normalization policy, emphasizing the necessity and urgency of reforming the health insurance system. Analysts say that it has virtually formalized the abolition of the policy to strengthen health insurance coverage, which is the core of the so-called "Moon Jae-in Care" promoted by the previous government.
- Company
- Severe asthma treatment Fasenra seeks reimb in KOR
- by Eo, Yun-Ho Dec 19, 2022 04:34am
- Another severe asthma treatment is attempting insurance reimbursement in Korea. According to industry sources, AstraZeneca is undergoing the reimbursement process for its monoclonal antibody for asthma, Fasenra (benralizumab). Other biological drugs including GSK’s ‘Nucala (mepolizumab),’ and Teva-Handok’s ‘Cinqair (reslizumab)’ hav
- Policy
- MFDS approves Jemperil, the third PD-1 inhibitor in Korea
- by Lee, Hye-Kyung Dec 15, 2022 05:55am
- The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) approved GlaxoSmithKline's new drug endometrial cancer treatment Jemperil on the 14th. Jemperil will be the third PD-1 inhibitor to be licensed in Korea after Opdivo of Ono and BMS and Keytgruda of MSD. Jemperil is a monoclonal antibody targeting cell predetermined history 1 (PD-1)
- Company
- Asthma treatment Cinqair attempts reimb again in Korea
- by Eo, Yun-Ho Dec 15, 2022 05:55am
- The asthma treatment Cinqair for asthma is again attempting reimbursement listing in Korea. According to industry sources, Teva-Handok has recently submitted an application for the reimbursement listing of its interleukin-5 antagonist monoclonal antibody Cinqair (reslizumab). Following Cinqair’s steps, other biological drugs for asthma i
- Company
- Verzenio expects to address the unmet demand
- by Eo, Yun-Ho Dec 15, 2022 05:55am
- Expectations are high for securing early breast cancer indications for Verzenio, a breast cancer treatment with CDK4/600 inhibition mechanism. Lilly Korea held a press conference on the 14th to commemorate the expansion of permission for early breast cancer indications at high risk of recurrence of the anticancer drug Verzenio. Verzenio obta
- Product
- Menarini Korea is expected to distribute Viagra
- by Kim JiEun Dec 15, 2022 05:55am
- Viagra, which was sold by Jeil, is likely to be distributed at Menarini from next month. According to the pharmaceutical industry on the 12th, Menarini is in charge of distributing urological treatments such as Viatris Korea's Viagra, Cadura, and Detrusitol. The move follows the termination of Viatris and Jeil's sales rights contract for thes
- Policy
- MFDS “Increasing AAP manufacturing well in progress”
- by Lee, Hye-Kyung Dec 14, 2022 05:57am
- To the issue that had been raised on how the supply shortage is continuing in the field even after increasing the price of acetaminophen, the Ministry of Food and Drug Safety replied that it has reviewed the monthly production schedule and the increase in production is progressing according to plan. Also, the MFDS added that the acetaminophen
- Company
- Samsung Epis's Soliris biosimilar bioequivalent to original
- by Dec 14, 2022 05:56am
- Study results that show Samsung Bioepis’s Soliris biosimilar is bioequivalent to the original drug have been presented. On the 13th, the company announced that its biosimilar, SB12 has demonstrated equal effect to its original drug Soliris at the American Society of Hematology (ASH) Annual Meeting that is being held in New Orleans.
- Company
- Champix supply interruption
- by Kim, Jin-Gu Dec 14, 2022 05:56am
- Jeil Pharmaceutical's Nico Chams has dominated the market for anti-smoking treatment aids with Varenicline ingredients. Analysts say that while sales of major products, including Pfizer Champix, were suspended due to the detection of impurities in NNV components in September last year, it succeeded in digging into the gap and raising its influen
- Company
- 2022 Pharmaceutical Industry Advertising Target Call Members
- by Dec 14, 2022 05:56am
- Daewon Pharmaceutical's "Coldewon" and Sanofi's "Honey Jam Market for Those Who Can't Sleep" won the grand prize in the advertising and PR categories at the 2022 Korea Pharmaceutical Bio-Industry Advertising and PR Awards. Chong Kun Dang Benfobell won the grand prize in the "Special Award for Pharmacist Selection" category, which was decided
